Merck agrees to support Johnson & Johnson in vaccine manufacturing deal
Funding from BARDA helps the company to adapt and make available a number of existing manufacturing facilities for the production of SARS-CoV-2 vaccines and medicines
In a deal brokered by the US Biden administration, US pharma firm Merck has agreed to help rival Johnson & Johnson's manufacturing of its recently approved single-shot COVID-19 vaccine.
Merck will make available two of its facilities for drug substance production and vial filling of the SARS-CoV-2 vaccine.
Announcing the deal at the White House on March 2, US President Joe Biden described the deal as “two of the largest pharmaceutical companies in the world who are usually competitors are working together on the vaccine."
"This is the type of collaboration between companies we saw in World War II," he added.
He said the arrangement has materialised because "among the things I learned when I came into office was that Johnson & Johnson was behind in manufacturing and production."
"We had the potential to have a highly effective vaccine to accompany the two existing vaccines. It simply wasn’t coming fast enough," he added.
According to J&J, Merck is the ninth manufacturer to join its global vaccine network.
In addition, Merck will receive up to $268.8 million of funding from the Biomedical Advanced Research and Development Authority (BARDA), a division within the US Department of Health and Human Services (HHS) to adapt and make available a number of existing manufacturing facilities for the production of COVID-19 vaccines and medicines.
Mike Nally, executive vice president, Human Health at Merck said: "This funding from BARDA will allow us to accelerate our efforts to scale up our manufacturing capacity to enable timely delivery of much-needed medicines and vaccines for the pandemic.”
This funding is in addition to Merck’s investment in its global vaccines manufacturing network as part of its planned capital investments of more than $20 billion from 2020 through the end of 2024.
Related News
-
News Pharmapack Awards 2024 Patient-Centric Design Award Winner – Dr Ferrer BioPharma
The 2024 Pharmapack Awards celebrated the best in innovation and design for the pharmaceutical packaging and drug delivery industry on January 24, 2024. -
News Women in Pharma: Minding the Gap at Pharmapack 2024
2024 marks the first year Pharmapack will host a Diversity track dedicated to bridging the gap within the pharmaceutical packaging and drug delivery sector. The track includes a panel discussion on 'Enabling Diversity in the Workplace,' focused... -
News Pharmapack Awards 2024 - Celebrating Packaging and Drug Delivery Innovation
The 2024 Pharmapack Innovation Awards ceremony celebrated the best in pharmaceutical packaging and drug delivery innovation at all levels. The awards were held on January 24, 2024 at the Paris Expo Porte de Versailles. -
News 2024 Pharma Industry Trends Outlook: Collaboration, Market Maturity, and Digital Futures
The annual CPHI Online 2024 Pharma Trends Outlook, in partnership with Arvato Systems, identifies 12 key industry trends shaping the life sciences industry in the coming year. -
News New Novo Nordisk AI hub for drug discovery to open in London, UK
Danish pharmaceutical giant Novo Nordisk will be opening an AI-based research facility in the heart of London to advance drug discovery operations. -
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Women in Pharma: Looking back on 2023 and moving forward to 2024
In this monthly series, we interview women from across the pharmaceutical industry and supply chain to discuss the importance of gender diversity in healthcare, the workplace, and beyond. -
News CPHI Barcelona 2023: Partnering for Success – Managing Outsourcing Relationships to Optimise Manufacturing Operations
During CPHI Barcelona 2023, insightful content sessions offered attendees the chance to explore trending topics with expert speakers and panellists. Here, we summarise what the pharma industry and supply chain are talking about the most.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance